Matthew Wein insider trades: Metagenomi Therapeutics (MGX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthew reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | MGX | ↓ Sell | 558 | $1.30 | $725 | Direct | Jun 10, 2026 (5d) |
| Mar 5, 2026 | MGX | ↓ Sell | 482 | $1.60 | $771 | Direct | Mar 9, 2026 (4d) |
| Dec 5, 2025 | MGX | ↓ Sell | 199 | $1.77 | $353 | Direct | Dec 8, 2025 (3d) |
| Sep 5, 2025 | MGX | ↓ Sell | 199 | $1.81 | $360 | Direct | Dec 1, 2025 (87d) |
| Jun 6, 2025 | MGX | ↓ Sell | 199 | $1.75 | $348 | Direct | Jun 9, 2025 (3d) |
| Mar 5, 2025 | MGX | ↓ Sell | 930 | $1.87 | $2K | Direct | Mar 7, 2025 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MGX insiders
Open-market trades in the last 12 months
About Matthew Wein's insider trades
Matthew Wein is See Remarks at Metagenomi Therapeutics (MGX). Since Mar 5, 2025, Matthew has reported no open-market purchases and 6 sales worth $4K on SEC Form 4. In the last 12 months: 3 sales ($2K).
Their filings also include grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MGX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.